Rev	isi	on	1
<b>Nev</b>	121	ULI	



Applications: W	<b>Reactivity:</b> H Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 75	<b>Source/Isotype:</b> Rabbit	<b>UniProt ID:</b> #O95365	Entrez-Gene Id 51341		
Product Usage Information		<b>Application</b> Western Blotting			Dilution 1:1000			
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% 20°C. Do not aliquot the antibody.				ycerol. Store at –		
Specificity/Sensitivity		LRF/Pokemon Antibody recognizes endogenous levels of total LRF (Pokemon) protein.						
Source / Purific	ation	Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro241 of human LRF (pokemon) protein. Antibodies are purified by protein A and peptide affinity chromatography.						
Background		Zinc finger and BTB domain-containing protein 7A (LRF, Pokemon, FBI1) is a transcriptional repressor encoded by the <i>ZBTB7A</i> gene that belongs to the POK (POZ and <i>Kruppel</i> )/ZBTB (zinc finger and BTB) family (1). LRF is broadly expressed with elevated expression in a variety of cancers relative to normal tissues, including non-small cell lung cancer, breast cancer, ovarian cancer, prostate cancer, and hepatocellular carcinoma (1-8). Research studies suggest that LRF acts as an oncogene through vario mechanisms including repression of the tumor suppressors ARF and Rb, and repression of the cell cy arrest factor p21Cip1 (9-11). The LRF transcription factor plays key roles during several stages of hematopoiesis including promoting lymphoid progenitor cells to commit to B cell differentiation by repressing T cell-promoting Notch signals, and promoting cell survival during terminal erythroid differentiation through suppression of the proapoptotic factor Bim (12,13).				finger and BTB) relative to normal cancer, and the through various sion of the cell cycle ral stages of fferentiation by		
Background Re	ferences	1. Lee, S.U. and Maed 2. Apostolopoulou, K. 3. Zhao, Z.H. et al. (20 4. Qu, H. et al. (2010) 5. Aggarwal, A. et al. ( 6. Jiang, L. et al. (2010) 7. Aggarwal, H. et al. 8. Fang, F. et al. (2012) 9. Maeda, T. et al. (20 10. Jeon, B.N. et al. (20 11. Choi, W.I. et al. (20 12. Maeda, T. et al. (20 13. Maeda, T. et al. (20	. et al. (2007) <i>J Patho</i> 008) <i>Lung Cancer</i> 62 <i>Cancer Invest</i> 28, 6 (2010) <i>Exp Mol Path</i> 0) <i>Mol Cancer</i> 9, 318 (2011) <i>Exp Mol Path</i> 2) <i>Cancer</i> 118, 134-4 05) <i>Nature</i> 433, 278 008) <i>J Biol Chem</i> 28 009) <i>J Biol Chem</i> 28 007) <i>Science</i> 316, 80	o/213, 294-302. , 113-9. 72-8. o/ 89, 140-8. o/ 90, 226-30. 6. -85. 3, 33199-210. I, 12633-44. 50-6.				
Species Reactiv	/ity	Species reactivity is d	etermined by testir	g in at least one approve	ed application (e.g.,	western blot).		
Western Blot BufferIMPORTANT: For western blots, incubate membrane with diluted p TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				primary antibody i	n 5% w/v BSA, 1X			
Applications Ke	∋y	W: Western Blotting						
Cross-Reactivit	у Кеу	H: Human Mk: Monk	ey					
Trademarks and Patents	d Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.						
		SignalSilence is a registered trademark of Cell Signaling Technology, Inc.						
		All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.						

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.